Jun 01, 2023 / 01:00PM GMT
Vincent Anzalone - Arrowhead Pharmaceuticals, Inc. - Head of IR & VP
Thanks so much for coming today. We're here for Arrowhead's Analyst R&D Day, and we have a lot to cover. So I'm just going to jump in. This is our safe harbor statement. Please refer to the risk factors in our SEC filings. We will be making forward-looking statements in today's presentations. So we've got a really good panel. Arrowhead folks as well as a few external folks who are experts in their disease areas. We have Michael Benatar from the University of Miami, who'll be talking about ALS and SOD1 specifically. We have Matthias Salathe from University of Kansas, who will be talking about the pulmonary programs, both inflammatory as well as the muco-obstructive program; and Ira Goldberg from NYU, who'll be talking about the cardiometabolic.
So like I said, there's a lot to cover today. This is the basic flow. We'll go over CNS. We'll go over some of the expansion that we're doing to the TRiM platform to get to new tissue types. Then we'll have a Q&A session in between each kind of topical area, short Q&A, about
Arrowhead Pharmaceuticals Inc R&D Day Transcript
Jun 01, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers